Sarcoidosis: a clinical overview from symptoms to diagnosis
P Sève, Y Pacheco, F Durupt, Y Jamilloux… - Cells, 2021 - mdpi.com
Sarcoidosis is a multi-system disease of unknown etiology characterized by the formation of
granulomas in various organs. It affects people of all ethnic backgrounds and occurs at any …
granulomas in various organs. It affects people of all ethnic backgrounds and occurs at any …
Idiopathic pulmonary fibrosis: state of the art for 2023
AJ Podolanczuk, CC Thomson… - European …, 2023 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …
Precision medicine advances in idiopathic pulmonary fibrosis
T Karampitsakos, BM Juan-Guardela, A Tzouvelekis… - …, 2023 - thelancet.com
Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown …
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown …
Idiopathic pulmonary fibrosis
FJ Martinez, HR Collard, A Pardo, G Raghu… - Nature reviews Disease …, 2017 - nature.com
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …
Idiopathic pulmonary fibrosis
L Richeldi, HR Collard, MG Jones - The Lancet, 2017 - thelancet.com
Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …
Syndrome of combined pulmonary fibrosis and emphysema: an official ATS/ERS/JRS/ALAT research statement
Background: The presence of emphysema is relatively common in patients with fibrotic
interstitial lung disease. This has been designated combined pulmonary fibrosis and …
interstitial lung disease. This has been designated combined pulmonary fibrosis and …
Progressive pulmonary fibrosis: an expert group consensus statement
This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
Six-minute walk test: clinical role, technique, coding, and reimbursement
P Agarwala, SH Salzman - Chest, 2020 - Elsevier
The 6-min walk test (6MWT) is a commonly used test for the objective assessment of
functional exercise capacity for the management of patients with moderate-to-severe …
functional exercise capacity for the management of patients with moderate-to-severe …
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
G Raghu, VC Amatto, J Behr… - European Respiratory …, 2015 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in
patients over 60 years old who may have comorbidities. The prevalence and impact of …
patients over 60 years old who may have comorbidities. The prevalence and impact of …
Short‐term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis
NS Goh, RK Hoyles, CP Denton… - Arthritis & …, 2017 - Wiley Online Library
Objective To determine the prognostic value of pulmonary function test (PFT) trends at 1 and
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …